FCGR2A and neoplasm: For several antitumor mAbs, such as anti‐HER‐2/neu, anti‐MUC1, or anti‐hCD20, there is evidence that in the first step, the mAbs rapidly kill the tumor cells via FcγR‐mediated antibody‐dependent cell cytotoxicity (ADCC), a mechanism by which myeloid cells in mice, and both myeloid and NK cells in humans, recognize and kill antibody‐coated cells.